Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153920 · ClinicalTrials.gov registry record · Phase 2
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT00153920 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 66 participants.
The verdict
NCT00153920, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Bortezomib (Velcade) has just recently been approved by the FDA for the treatment of multiple myeloma in patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. This study will determine if Velcade is effective in treating patients with multiple myeloma that have had no prior treatment for the disease. We will also use whole-genome scanning to identify drug response biomarkers in bone marrow samples as well as nerve fiber studies to compare nerves prior to the use of Velcade and after treatment with Velcade.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2003-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153920
The ClinicalTrials.gov registry entry for NCT00153920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00153920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153920 about?
NCT00153920 is a clinical study titled "Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma". Bortezomib (Velcade) has just recently been approved by the FDA for the treatment of multiple myeloma in patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. This study will determine if Velcade is effective in treating patients with ...
What is the current status of trial NCT00153920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2003-12. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00153920?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00153920?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.